dc.contributor.author | Peña Asensio, Julia | |
dc.contributor.author | Calvo Sánchez, Henar | |
dc.contributor.author | Torralba González de Suso, Miguel | |
dc.contributor.author | Miquel Plaza, Joaquín | |
dc.contributor.author | Sanz de Villalobos, Eduardo | |
dc.contributor.author | Larrubia Marfil, Juan Ramón | |
dc.date.accessioned | 2022-03-01T09:17:43Z | |
dc.date.available | 2022-03-01T09:17:43Z | |
dc.date.issued | 2021-04-16 | |
dc.identifier.bibliographicCitation | Cancers, 2021, v. 13, n. 8, p. 1922 | en |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://hdl.handle.net/10017/50894 | |
dc.description | Peña-Asensio, J.; Calvo, H.; Torralba, M.; Miquel, J.; Sanz-de-Villalobos, E.; Larrubia, J.-R. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers 2021, 13, 1922. | en |
dc.description.abstract | Thirty to fifty percent of hepatocellular carcinomas (HCC) display an immune class genetic
signature. In this type of tumor, HCC-specific CD8 T cells carry out a key role in HCC control. Those
potential reactive HCC-specific CD8 T cells recognize either HCC immunogenic neoantigens or
aberrantly expressed host’s antigens, but they become progressively exhausted or deleted. These cells
express the negative immunoregulatory checkpoint programmed cell death protein 1 (PD-1) which
impairs T cell receptor signaling by blocking the CD28 positive co-stimulatory signal. The pool of CD8
cells sensitive to anti-PD-1/PD-L1 treatment is the PD-1dim memory-like precursor pool that gives
rise to the effector subset involved in HCC control. Due to the epigenetic imprints that are transmitted
to the next generation, the effect of PD-1 blockade is transient, and repeated treatments lead to tumor
resistance. During long-lasting disease, besides the TCR signaling impairment, T cells develop other
failures that should be also set-up to increase T cell reactivity. Therefore, several PD-1 blockade-based
combinatory therapies are currently under investigation such as adding antiangiogenics, anti-TGFβ1,
blockade of other negative immune checkpoints, or increasing HCC antigen presentation. The effect of these combinations on CD8+ T cells is discussed in this review. | en |
dc.description.sponsorship | Instituto de Salud Carlos III | es |
dc.description.sponsorship | European Regional Development Fund (ERDF) | en |
dc.description.sponsorship | European Union | en |
dc.description.sponsorship | Gilead Fellowship Programme | en |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.rights | © 2021 by the authors. Licensee MDPI | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.subject | Hepatocellular carcinoma | en |
dc.subject | Immunotherapy | en |
dc.subject | PD-1 | en |
dc.subject | PD-L1 | en |
dc.subject | Immune check-point inhibitor | en |
dc.subject | Combination therapy | en |
dc.subject | CD8 T cell response | en |
dc.title | Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. | en |
dc.type | info:eu-repo/semantics/article | en |
dc.subject.eciencia | Medicina | es |
dc.subject.eciencia | Medicine | es |
dc.contributor.affiliation | Universidad de Alcalá. Departamento de Medicina y Especialidades Médicas | es |
dc.date.updated | 2022-03-01T09:06:31Z | |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.identifier.doi | 10.3390/cancers13081922 | |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/ PI19%2F00206/ES/ | es |
dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Sciences/ Gilead Fellowship Program in HIV & Hepatitis/ GLD14%2F00217 (JRL)/ES/ | en |
dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Sciences/ Gilead Fellowship Program in HIV & Hepatitis/ GLD16/00014 (JRL)/ES/ | en |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | en |
dc.identifier.uxxi | AR/0000040467 | |
dc.identifier.publicationtitle | Cancers | en |
dc.identifier.publicationvolume | 13 | |
dc.identifier.publicationissue | 8 | |
dc.identifier.publicationfirstpage | 1922 | |